Method of treating and preventing secondary hyperparathyroidism
View Patent ↗The a method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance.
1. A method of increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a human patient, comprising administering both Vitamin D repletion and Vitamin D hormone replacement therapies, wherein the blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL while avoiding supraphysiologic levels, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D.
2. A method of concurrently lowering or maintaining plasma iPTH levels, increasing or maintaining serum calcium levels, maintaining serum phosphorous levels, increasing or maintaining serum 25-hydroxyvitamin D while avoiding supraphysiologic levels, and increasing or maintaining serum 1,25-dihydroxyvitamin D levels in a human patient by administering to the patient both Vitamin D repletion and Vitamin D hormone replacement therapies.
3. A method of reducing the risk of over suppression of plasma iPTH levels in a patient undergoing treatment for elevated levels of plasma iPTH, comprising administering both Vitamin D repletion and Vitamin D hormone replacement therapies in amounts sufficient to decrease elevated plasma iPTH levels while avoiding supraphysiologic blood concentrations of 25-hydroxyvitamin D.
4. A method of maintaining in a patient blood concentrations of 25-hydroxyvitamin D at or above 30 ng/mL, while avoiding supraphysiologic levels, and blood concentrations of 1,25-dihydroxyvitamin D in a patient at levels within the patient's normal historical physiological range, while lowering elevated blood levels of iPTH without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH, comprising administering to the patient an effective amount, as needed, of both a Vitamin D repletion therapy and a Vitamin D hormone replacement therapy.
5. The method according to claim 1 , wherein the blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL while avoiding supraphysiologic levels between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.
6. The method according to claim 1 , wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 .
7. The method according to claim 1 , wherein the administering of Vitamin D repletion comprises administering predominantly 25-hydroxyvitamin D 3 .
8. The method according to claim 1 , wherein the administering of Vitamin D repletion therapy comprises controllably releasing a compound for Vitamin D repletion.
9. The method according to claim 1 , wherein the administering of Vitamin D hormone replacement therapy comprises controllably releasing a compound for Vitamin D hormone replacement.
10. The method according to claim 1 , wherein the patient suffers from chronic kidney disease.
11. The method of claim 10 , wherein the chronic kidney disease is Stage 1, Stage 2, Stage 3, or Stage 4.
12. The method of claim 10 , wherein the chronic kidney disease is Stage 3, Stage 4, or Stage 5.
13. The method of claim 12 , wherein the chronic kidney disease is Stage 3 or Stage 4.
14. The method of claim 12 , wherein the chronic kidney disease is Stage 5.
15. The method according to claim 1 , further comprising co-treatment with a phosphate binder.
16. The method according to claim 1 , further comprising co-treatment with a calcimimetic agent.
17. The method according to claim 2 , wherein the administering of Vitamin D repletion comprises administering predominantly 25-hydroxyvitamin D 3 .
18. The method according to claim 3 , wherein the administering of Vitamin D repletion comprises administering predominantly 25-hydroxyvitamin D 3 .
19. The method according to claim 4 , wherein the administering of Vitamin D repletion comprises administering predominantly 25-hydroxyvitamin D 3 .
20. The method according to claim 2 , wherein the patient suffers from chronic kidney disease.
21. The method of claim 3 , comprising decreasing elevated plasma iPTH levels while avoiding an abnormally low bone turnover rate.
22. The method of claim 1 , wherein the Vitamin D repletion therapy is administered orally.
23. The method of claim 2 , wherein the Vitamin D repletion therapy is administered orally.
24. The method of claim 3 , wherein the Vitamin D repletion therapy is administered orally.
25. The method of claim 4 , wherein the Vitamin D repletion therapy is administered orally.